UTHR Q3 2024 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$749M+22.9% YoY

Gross Profit

$666M88.9% margin

Operating Income

$343M45.8% margin

Net Income

$309M41.3% margin

EPS (Diluted)

$6.39

QoQ Revenue Growth

+4.8%

Cash Flow

Operating Cash Flow

$377M

Free Cash Flow

$301M

Stock-Based Comp.

$42M

Balance Sheet

Total Assets

$7.1B

Total Liabilities

$1.0B

Stockholders' Equity

$6.1B

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$749M	$609M	+22.9%
Gross Profit	$666M	$539M	+23.5%
Operating Income	$343M	$327M	+4.9%
Net Income	$309M	$268M	+15.5%

Revenue Segments

Tyvaso

$434M58%

Remodulin

$128M17%

Orenitram

$113M15%

Unituxin

$61M8%

Adcirca

$7M1%

Product and Service, Other

$6M1%

Geographic Segments

UNITED STATES

$717M96%

Non-US

$32M4%